Cargando…

Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleinstern, Geffen, Larson, Dirk R., Allmer, Cristine, Norman, Aaron D., Muntifering, Grace, Sinnwell, Jason, Visram, Alissa, Rajkumar, Vincent, Dispenzieri, Angela, Kyle, Robert A., Slager, Susan L., Kumar, Shaji, Vachon, Celine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018764/
https://www.ncbi.nlm.nih.gov/pubmed/35440099
http://dx.doi.org/10.1038/s41408-022-00659-9
_version_ 1784689099169333248
author Kleinstern, Geffen
Larson, Dirk R.
Allmer, Cristine
Norman, Aaron D.
Muntifering, Grace
Sinnwell, Jason
Visram, Alissa
Rajkumar, Vincent
Dispenzieri, Angela
Kyle, Robert A.
Slager, Susan L.
Kumar, Shaji
Vachon, Celine M.
author_facet Kleinstern, Geffen
Larson, Dirk R.
Allmer, Cristine
Norman, Aaron D.
Muntifering, Grace
Sinnwell, Jason
Visram, Alissa
Rajkumar, Vincent
Dispenzieri, Angela
Kyle, Robert A.
Slager, Susan L.
Kumar, Shaji
Vachon, Celine M.
author_sort Kleinstern, Geffen
collection PubMed
description Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical factors in a population-based study. We identified 594 MGUS through a population-based screening study in Olmsted County, Minnesota, between 1995 and 2003. Follow-up time was calculated from the date of MGUS to last follow-up, death, or progression to MM/another plasma-cell/lymphoid disorder. BMI (kg/m(2) < 25/≥25) was measured close to screening date. We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of BMI ≥ 25 versus BMI < 25 with MGUS progression and also evaluated the corresponding c-statistic and 95% CI to describe discrimination of the model for MGUS progression. Median follow-up was 10.5 years (range:0–25), while 465 patients died and 57 progressed and developed MM (N = 39), AL amyloidosis (N = 8), lymphoma (N = 5), or Waldenstrom-macroglobulinemia (N = 5). In univariate analyses, BMI ≥ 25 (HR = 2.14,CI:1.05–4.36, P = 0.04), non-IgG (HR = 2.84, CI:1.68–4.80, P = 0.0001), high monoclonal (M) protein (HR = 2.57, CI:1.50–4.42, P = 0.001), and abnormal free light chain ratio (FLC(r)) (HR = 3.39, CI:1.98–5.82, P < 0.0001) were associated with increased risk of MGUS progression, and were independently associated in a multivariable model (c-statistic = 0.75, CI:0.68–0.82). The BMI association was stronger among females (HR = 3.55, CI:1.06–11.9, P = 0.04) vs. males (HR = 1.39, CI:0.57–3.36, P = 0.47), although the interaction between BMI and sex was not significant (P = 0.15). In conclusion, high BMI is a prognostic factor for MGUS progression, independent of isotype, M protein, and FLC(r). This association may be stronger among females.
format Online
Article
Text
id pubmed-9018764
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-90187642022-04-28 Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota Kleinstern, Geffen Larson, Dirk R. Allmer, Cristine Norman, Aaron D. Muntifering, Grace Sinnwell, Jason Visram, Alissa Rajkumar, Vincent Dispenzieri, Angela Kyle, Robert A. Slager, Susan L. Kumar, Shaji Vachon, Celine M. Blood Cancer J Article Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical factors in a population-based study. We identified 594 MGUS through a population-based screening study in Olmsted County, Minnesota, between 1995 and 2003. Follow-up time was calculated from the date of MGUS to last follow-up, death, or progression to MM/another plasma-cell/lymphoid disorder. BMI (kg/m(2) < 25/≥25) was measured close to screening date. We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of BMI ≥ 25 versus BMI < 25 with MGUS progression and also evaluated the corresponding c-statistic and 95% CI to describe discrimination of the model for MGUS progression. Median follow-up was 10.5 years (range:0–25), while 465 patients died and 57 progressed and developed MM (N = 39), AL amyloidosis (N = 8), lymphoma (N = 5), or Waldenstrom-macroglobulinemia (N = 5). In univariate analyses, BMI ≥ 25 (HR = 2.14,CI:1.05–4.36, P = 0.04), non-IgG (HR = 2.84, CI:1.68–4.80, P = 0.0001), high monoclonal (M) protein (HR = 2.57, CI:1.50–4.42, P = 0.001), and abnormal free light chain ratio (FLC(r)) (HR = 3.39, CI:1.98–5.82, P < 0.0001) were associated with increased risk of MGUS progression, and were independently associated in a multivariable model (c-statistic = 0.75, CI:0.68–0.82). The BMI association was stronger among females (HR = 3.55, CI:1.06–11.9, P = 0.04) vs. males (HR = 1.39, CI:0.57–3.36, P = 0.47), although the interaction between BMI and sex was not significant (P = 0.15). In conclusion, high BMI is a prognostic factor for MGUS progression, independent of isotype, M protein, and FLC(r). This association may be stronger among females. Nature Publishing Group UK 2022-04-19 /pmc/articles/PMC9018764/ /pubmed/35440099 http://dx.doi.org/10.1038/s41408-022-00659-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kleinstern, Geffen
Larson, Dirk R.
Allmer, Cristine
Norman, Aaron D.
Muntifering, Grace
Sinnwell, Jason
Visram, Alissa
Rajkumar, Vincent
Dispenzieri, Angela
Kyle, Robert A.
Slager, Susan L.
Kumar, Shaji
Vachon, Celine M.
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota
title Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota
title_full Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota
title_fullStr Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota
title_full_unstemmed Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota
title_short Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota
title_sort body mass index associated with monoclonal gammopathy of undetermined significance (mgus) progression in olmsted county, minnesota
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018764/
https://www.ncbi.nlm.nih.gov/pubmed/35440099
http://dx.doi.org/10.1038/s41408-022-00659-9
work_keys_str_mv AT kleinsterngeffen bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT larsondirkr bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT allmercristine bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT normanaarond bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT muntiferinggrace bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT sinnwelljason bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT visramalissa bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT rajkumarvincent bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT dispenzieriangela bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT kyleroberta bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT slagersusanl bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT kumarshaji bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota
AT vachoncelinem bodymassindexassociatedwithmonoclonalgammopathyofundeterminedsignificancemgusprogressioninolmstedcountyminnesota